Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

VYNE Therapeutics (VYNE) Amortization of Deferred Charges (2019)

VYNE Therapeutics' Amortization of Deferred Charges history spans 1 years, with the latest figure at $160000.0 for Q4 2019.

For Q4 2019, Amortization of Deferred Charges changed N/A year-over-year to $160000.0; the TTM value through Dec 2019 reached $737000.0, changed N/A, while the annual FY2019 figure was $644000.0, N/A changed from the prior year.
Amortization of Deferred Charges reached $160000.0 in Q4 2019 per VYNE's latest filing, down from $200000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $200000.0 in Q2 2019 to a low of $160000.0 in Q4 2019.